See more : Talanx AG (TLLXY) Income Statement Analysis – Financial Results
Complete financial analysis of Lukas Biomedical Inc. (6814.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lukas Biomedical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Great Panther Mining Limited (GPL) Income Statement Analysis – Financial Results
- Impex Ferro Tech Limited (IMPEXFERRO.NS) Income Statement Analysis – Financial Results
- Ibere Pharmaceuticals (IBER-UN) Income Statement Analysis – Financial Results
- EIH Limited (EIHOTEL.BO) Income Statement Analysis – Financial Results
- Tritent International Corp. (TICJ) Income Statement Analysis – Financial Results
Lukas Biomedical Inc. (6814.TWO)
About Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the development of immune cell medical technology for regenerative medicine and auxiliary treatment of cancer in Taiwan. It operates through four divisions: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. The company also wholesales and retails cosmetics; and rents housing equipment. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 231.83M | 184.79M | 157.62M | 181.41M | 152.89M |
| Cost of Revenue | 97.94M | 86.88M | 61.56M | 62.96M | 52.73M |
| Gross Profit | 133.89M | 97.91M | 96.06M | 118.45M | 100.16M |
| Gross Profit Ratio | 57.75% | 52.98% | 60.95% | 65.29% | 65.51% |
| Research & Development | 77.33M | 55.92M | 54.98M | 35.39M | 29.20M |
| General & Administrative | 35.45M | 31.61M | 30.34M | 27.88M | 25.95M |
| Selling & Marketing | 64.67M | 58.95M | 55.00M | 61.85M | 52.08M |
| SG&A | 100.12M | 90.55M | 85.33M | 89.73M | 78.03M |
| Other Expenses | 0.00 | 1.39M | -397.00K | 140.00K | -17.00K |
| Operating Expenses | 177.45M | 146.48M | 140.31M | 125.11M | 107.23M |
| Cost & Expenses | 275.39M | 233.36M | 201.87M | 188.07M | 159.96M |
| Interest Income | 0.00 | 73.00K | 43.00K | 40.00K | 56.00K |
| Interest Expense | 0.00 | 2.92M | 4.42M | 4.83M | 5.19M |
| Depreciation & Amortization | 17.26M | 36.07M | 43.06M | 48.40M | 50.26M |
| EBITDA | -26.30M | -10.93M | -361.00K | 43.28M | 43.23M |
| EBITDA Ratio | -11.34% | -5.97% | -0.98% | 23.11% | 28.27% |
| Operating Income | -43.56M | -47.10M | -44.60M | -6.48M | -7.03M |
| Operating Income Ratio | -18.79% | -25.49% | -28.30% | -3.57% | -4.60% |
| Total Other Income/Expenses | -3.72M | -1.35M | -3.58M | -3.48M | -761.00K |
| Income Before Tax | -47.28M | -49.92M | -47.83M | -9.96M | -7.79M |
| Income Before Tax Ratio | -20.39% | -27.01% | -30.35% | -5.49% | -5.10% |
| Income Tax Expense | 78.00K | 151.00K | 1.66M | 586.00K | -802.00K |
| Net Income | -47.35M | -50.07M | -49.49M | -10.54M | -6.99M |
| Net Income Ratio | -20.43% | -27.10% | -31.40% | -5.81% | -4.57% |
| EPS | -1.28 | -1.35 | -1.50 | -0.32 | -0.20 |
| EPS Diluted | -1.28 | -1.35 | -1.50 | -0.32 | -0.20 |
| Weighted Avg Shares Out | 36.87M | 37.01M | 33.08M | 33.08M | 34.10M |
| Weighted Avg Shares Out (Dil) | 36.87M | 37.01M | 33.08M | 33.08M | 34.10M |
Source: https://incomestatements.info
Category: Stock Reports